menu
    • menu

    Company profile for Hemab Therapeutics

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.The right time for Hema...
    Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.The right time for Hemab Therapeutics - a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Hemab TherapeuticsDenmark Flag
    Country
    Country
    Denmark
    Address
    Address
    Ole Maaløes Vej 3, Copenhagen, Capital Region 2200
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://hemab.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/hemabaps/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novo-Backed Biotech Hemab Seeks To Raise $212 Million In US IPO
    Novo-Backed Biotech Hemab Seeks To Raise $212 Million In US IPO

    27 Apr 2026

    // BLOOMBERG

    https://www.bloomberg.com/news/articles/2026-04-27/novo-backed-biotech-hemab-seeks-to-raise-212-million-in-us-ipo

    BLOOMBERG
    27 Apr 2026
    Share Share
    Seaport, Hemab Prepare Ipos To Fund Depression, Clotting Drugs
    Seaport, Hemab Prepare Ipos To Fund Depression, Clotting Drugs

    13 Apr 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/seaport-prepares-ipo-voyage-fund-depression-drugs-journey-phase-3

    FIERCE BIOTECH
    13 Apr 2026
    Share Share
    Hemab Pharma Granted FDA Breakthrough Status For Sutacimig
    Hemab Pharma Granted FDA Breakthrough Status For Sutacimig

    05 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hemab-therapeutics-receives-fda-breakthrough-therapy-designation-for-sutacimig-in-glanzmann-thrombasthenia-302704598.html

    PR NEWSWIRE
    05 Mar 2026
    Share Share
    Hemab Therapeutics Advances Sutacimig For Glanzmann
    Hemab Therapeutics Advances Sutacimig For Glanzmann

    09 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hemab-therapeutics-announces-positive-complete-phase-2-data-for-sutacimig-in-glanzmann-thrombasthenia-at-ash-2025-plans-to-advance-to-pivotal-phase-3-study-302634302.html

    PR NEWSWIRE
    09 Dec 2025
    Share Share
    Hemab Therapeutics Secures $157M For Bleeding Disorder Treatments
    Hemab Therapeutics Secures $157M For Bleeding Disorder Treatments

    27 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hemab-therapeutics-announces-157-million-series-c-financing-to-advance-next-generation-treatments-for-underserved-bleeding-disorders-302594712.html

    PR NEWSWIRE
    27 Oct 2025
    Share Share
    Hemab Therapeutics Names Anant Murthy, PhD, Chief Operating
    Hemab Therapeutics Names Anant Murthy, PhD, Chief Operating

    02 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hemab-therapeutics-expands-leadership-with-appointment-of-anant-murthy-phd-as-chief-operating-officer-302543182.html

    PR NEWSWIRE
    02 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search